Ancora Heart Secures $80 Million in Financing
Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.
- Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.
- Ancora Heart is at an exciting stage as we continue with our pivotal clinical trial to support our PMA submission to the FDA, and this investment will help us prepare for potential launch and subsequent commercialization, said Jeff Closs, president and CEO of Ancora Heart.
- About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency.
- (ClinicalTrials.gov Identifier: NCT03183895 )
Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF).